MA53875A - Traitement avec des compositions d'igg hautement sialylées - Google Patents

Traitement avec des compositions d'igg hautement sialylées

Info

Publication number
MA53875A
MA53875A MA053875A MA53875A MA53875A MA 53875 A MA53875 A MA 53875A MA 053875 A MA053875 A MA 053875A MA 53875 A MA53875 A MA 53875A MA 53875 A MA53875 A MA 53875A
Authority
MA
Morocco
Prior art keywords
treatment
highly sialylated
igg compositions
sialylated igg
compositions
Prior art date
Application number
MA053875A
Other languages
English (en)
Inventor
Santiago Arroyo
William Denney
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MA53875A publication Critical patent/MA53875A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA053875A 2018-10-11 2019-10-11 Traitement avec des compositions d'igg hautement sialylées MA53875A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744536P 2018-10-11 2018-10-11
US201962879930P 2019-07-29 2019-07-29

Publications (1)

Publication Number Publication Date
MA53875A true MA53875A (fr) 2021-08-18

Family

ID=70164359

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053875A MA53875A (fr) 2018-10-11 2019-10-11 Traitement avec des compositions d'igg hautement sialylées

Country Status (11)

Country Link
US (1) US20210353752A1 (fr)
EP (1) EP3863673A4 (fr)
JP (1) JP2022502466A (fr)
KR (1) KR20210077706A (fr)
CN (1) CN113438953A (fr)
AU (1) AU2019357842A1 (fr)
BR (1) BR112021006852A2 (fr)
CA (1) CA3115821A1 (fr)
IL (1) IL282136A (fr)
MA (1) MA53875A (fr)
WO (1) WO2020077298A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
US20230192814A1 (en) * 2020-05-19 2023-06-22 Momenta Pharmaceuticals, Inc. Hyper-sialylated immunoglobulin
EP4199966A4 (fr) * 2020-08-20 2024-09-25 Momenta Pharmaceuticals Inc Glycoprotéines sialylées
EP4200431A4 (fr) * 2020-08-21 2024-09-25 Momenta Pharmaceuticals Inc Immunoglobuline hypersialylée
WO2024136368A1 (fr) * 2022-12-21 2024-06-27 건국대학교 산학협력단 UTILISATION D'IMMUNOGLOBULINE α-2,6-SIALYLÉE DANS LA PRÉVENTION OU LE TRAITEMENT DU SYNDROME DE L'ŒIL SEC OU DE MALADIES OCULAIRES INFLAMMATOIRES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456351A1 (fr) * 2006-04-05 2019-03-20 The Rockefeller University Polypeptides présentant des propriétés anti-inflammatoires améliorées et des propriétés cytotoxiques réduites et procédés afférents
TWI532498B (zh) * 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2778158A1 (fr) * 2009-10-22 2011-04-28 Eiger Health Partners, Llc Compositions, procedes de traitement et de diagnostic de troubles lies a l'auto-immunite et procede de fabrication de telles compositions
WO2014018747A2 (fr) * 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoprotéines ayant des propriétés anti-inflammatoires
WO2014179601A2 (fr) * 2013-05-02 2014-11-06 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
US10464996B2 (en) * 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US20160257754A1 (en) * 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
CN106232810A (zh) * 2014-01-29 2016-12-14 安吉酶迪卡公司 新的治疗
KR102477536B1 (ko) * 2016-03-30 2022-12-13 에이비 바이오사이언시즈 인코포레이티드 재조합 정맥내 면역글로불린(rIVIG) 조성물 및 이의 제조 및 사용 방법
CN110100007B (zh) * 2016-12-21 2024-05-28 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的酶的再使用

Also Published As

Publication number Publication date
AU2019357842A1 (en) 2021-05-13
CA3115821A1 (fr) 2020-04-16
WO2020077298A1 (fr) 2020-04-16
KR20210077706A (ko) 2021-06-25
EP3863673A1 (fr) 2021-08-18
JP2022502466A (ja) 2022-01-11
BR112021006852A2 (pt) 2021-08-17
US20210353752A1 (en) 2021-11-18
WO2020077298A9 (fr) 2020-05-22
CN113438953A (zh) 2021-09-24
IL282136A (en) 2021-05-31
EP3863673A4 (fr) 2023-01-11

Similar Documents

Publication Publication Date Title
MA53875A (fr) Traitement avec des compositions d'igg hautement sialylées
MA45192A (fr) Traitement d'association
IL281210A (en) Preparations for the treatment of the disease with conjugates that stimulate the immune system
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
MA49664A (fr) Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
GB202020354D0 (en) Compositions for the treatment of disease with immune stimulatory conjugates
MA54276A (fr) Montélukast de traitement de l'ostéoarthrite érosive de la main
MA54237A (fr) Composition attractive de l'espèce delottococcus aberiae
GB201820756D0 (en) MJ's-vimana
IT201700057247A1 (it) Agenti chelanti per il trattamento di disturbi nutrizionali di piante
FR3052669B1 (fr) Prothese biologique destinee au traitement des hernies parastomales
IT201800009293A1 (it) "divano"
MA54067A (fr) Traitement et prévention de l'éjaculation précoce (pe)
UA39819S (uk) Кондитерський виріб «колечко грильяжне»
MA49682A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
UA38254S (uk) Кольє «цепочокер»
UA40267S (uk) Гайка з'єднувальна
IT201900021909A1 (it) Stampella ortopedica elettromeccanica "pinfarina"
UA38339S (uk) Печиво «g digestive»
UA38939S (uk) Велобіг-мотоцикл дитячий
UA41385S (uk) Сковорода «talko»